Early low-dose lenalidomide significantly reduces mutational burden without increasing AML risk in non-transfusion-dependent del(5q) MDS.

Tregzi (clinically known as Orca-T) is an allogeneic cellular immunotherapy consisting of purified regulatory and conventional T cells.

Low MAR consistently identified patients with more favorable long-term outcomes across subgroups. Preoperative monocyte-to-albumin ratio (MAR) independently predicted overall survival (OS) in patients ...

A recent study assessed how future greenhouse gas emission trajectories may affect the heat-attributable burden of cardiovascular disease.

In this study, the researchers aimed to identify 5- and 10-year relative survival outcomes for individuals aged younger than 20 years at the time of a cancer diagnosis.

A real-world analysis investigates the impact of concurrent GLP-1 RA use on long-term survival and the safety profile of patients with solid and hematologic malignancies receiving immune checkpoint ...

This retrospective cohort analysis evaluates the prevalence of brain metastases in patients with advanced nonanaplastic thyroid cancer to determine the clinical utility of routine neurological ...

Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.

A retrospective study evaluates the use of antibiotic lock therapy as a catheter-sparing strategy in pediatric patients with hematologic and oncologic diseases.

A preliminary injunction preserves higher federal student loan limits for eligible NP and PA students while litigation continues.

A multicenter randomized clinical trial evaluates the impact of an app-facilitated digital symptom monitoring strategy with nurse-led follow-up on health-related quality of life and hospital ...

West Health and Gallup drew on self-reported experiences from nationally representative surveys to categorize individuals into 1 of 3 groups based on their ability to afford and access needed care.